The effect of 12-month dehydroepiandrosterone supplementation on the menstrual pattern, ovarian reserve markers, and safety profile in women with premature ovarian insufficiency

J Assist Reprod Genet. 2018 May;35(5):857-862. doi: 10.1007/s10815-018-1152-2. Epub 2018 Mar 9.

Abstract

Purpose: To evaluate the effect of 12-month DHEA supplementation on menstrual pattern and ovarian reserve markers in women with premature ovarian insufficiency (POI) METHODS: This is a prospective observational study. Women with POI were given DHEA supplements (25 mg three times daily) for 12 months. Sonographic assessment for ovarian volume and antral follicle count (AFC) and serum measurement for anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH), estradiol, testosterone, liver function, and hemoglobin level were performed at baseline and monthly for 13 months after the supplementation. Menstrual pattern, ovarian reserve markers, and side-effects were recorded.

Results: Between August 2011 and July 2014, 38 women with POI were recruited and 31 completed the study. The median age of women was 36 years, and the median baseline FSH and AMH concentrations were 82.2 IU/L and 0.01 ng/ml, respectively. No women had resumption of regular menstruation after DHEA supplementation. AMH, FSH, and AFC did not change significantly. No serious side effects were reported.

Conclusions: Our results do not support any significant improvement in ovarian function by 12-month DHEA supplementation in women with POI.

Keywords: Anti-Mullerian hormone; Antral follicle count; Dehydroepiandrosterone; Follicle-stimulating hormone; Premature ovarian insufficiency.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Anti-Mullerian Hormone / blood
  • Biomarkers / blood*
  • Dehydroepiandrosterone / adverse effects
  • Dehydroepiandrosterone / therapeutic use*
  • Estradiol / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Menstrual Cycle / drug effects*
  • Ovarian Reserve / drug effects*
  • Primary Ovarian Insufficiency / drug therapy*
  • Prospective Studies
  • Testosterone / blood

Substances

  • Biomarkers
  • Testosterone
  • Dehydroepiandrosterone
  • Estradiol
  • Anti-Mullerian Hormone
  • Follicle Stimulating Hormone